HDAX Therapeutics Announces First Closing of Oversubscribed US $3.2 Million Seed Financing

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

HDAX Therapeutics, a biotechnology company pioneering a novel approach to targeting HDAC6 for the discovery and development of breakthrough therapeutics for high unmet medical needs, announced the first closing of an oversubscribed US$3.2 (CA$4.3) million seed round. Proceeds from this financing will support the company’s progress towards preclinical development candidate nomination and further advancement of its pipeline programs.

HDAX Therapeutics is an OBIO® member, alumnus of our BDSP™, HealthMINT™ and WiHI programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Study Demonstrates Reveal 35C’s Impact in the ICU
Next

Canadian Medical Technology Consortium Collaborates on State-of-the-Art Postoperative Patient Management Platform, Led by FluidAI